Healthcare - Biotechnology - NASDAQ - US
$ 0.7096
4.21 %
$ 25.1 M
Market Cap
-3.09
P/E
CASH FLOW STATEMENT
-21.8 M
OPERATING CASH FLOW
-4.76 M
INVESTING CASH FLOW
-9.23 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Equillium, Inc.
| Net Income | -13.3 M |
| Depreciation & Amortization | 126 K |
| Capital Expenditures | -50 K |
| Stock-Based Compensation | 4 M |
| Change in Working Capital | -2.55 M |
| Others | -12.4 M |
| Free Cash Flow | -21.8 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (13.3) | (62.4) | (39.1) | (29.8) | (25.6) | (13.3) | (2.3) |
| Depreciation & Amortization | 0.1 | 0.1 | 72 K | 45 K | 23 K | 6.1 K | 122 |
| Deferred Income Tax | 0 | 0 | 0.6 | (0.3) | (0.4) | 0 | 0 |
| Stock Based Compensation | 4.0 | 4.8 | 4.4 | 3.8 | 2.3 | 0.4 | 0 |
| Other Operating Activities | (10.0) | 48.7 | 0.2 | 0.3 | 47 K | 5.0 | 1.2 |
| Change in Working Capital | (2.5) | 19 K | 1.7 | 1.3 | 0.7 | 0.3 | 0.4 |
| Cash From Operations | (21.8) | (8.7) | (32.1) | (24.6) | (22.9) | (7.5) | (0.7) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | 50 K | (0.3) | 57 K | (0.2) | 74 K | 34.9 K | 2.2 K |
| Other Items | (4.7) | 19.0 | 27.5 | (18.4) | (2.1) | (37.4) | 0 |
| Cash From Investing Activities | (4.8) | 18.7 | 27.4 | (18.6) | (2.2) | (37.4) | 2.2 K |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | (0.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (9.1) | (1.4) | 0 | 0 | 9.9 | 1.6 | 7.8 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.2 | 0.2 | 1.2 | 0.2 | 0.1 | 0.3 | 0 |
| Cash From Financing Activities | (9.2) | (1.2) | 31.1 | 53.9 | 9.8 | 66.4 | 7.8 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | (35.9) | 8.7 | 26.4 | 10.8 | (15.3) | 21.4 | 7.1 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (21.8) | (9.0) | (32.1) | (24.8) | (23.0) | (7.6) | (0.7) |